SEARCH

SEARCH BY CITATION

References

  • 1
    Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus; functional assessment, proposed pathogenesis and surgical therapy. Arch Surg 1983; 118: 5439.
  • 2
    Cooper BT, Barbezat GO. Barrett's oesophagus. A clinical study of 52 cases. Q J Med 1987; 62: 97108.
  • 3
    Tytgat GNJ, Hammeetman W, Onstenk RR, Scotberg R. The spectrum of columnar lined (Barrett's) oesophagus. Endoscopy 1989; 21: 17785.
  • 4
    Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histological spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 47680.
  • 5
    Rothery GA, Patterson JE, Stoddard CJ, Day DW. Histological and histochemical changes in the columnar lined (Barrett's) oesophagus. Gut 1986; 27: 10628.
  • 6
    Skinner DB, Walther BC, Riddell RH, Schmid H, Iascone C, DeMeester TR. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983; 198: 55465.
  • 7
    Spechler SJ, Robbins AH, Rubin HB, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87: 92735.
  • 8
    Kerlin P, Mellow GD, van Deth A. Barrett's oesophagus. Clinical endoscopic and histologic spectrum in 50 cases. Aust N Z J Med 1986; 16: 198205.
  • 9
    Reid BJ, Haggitt RG, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk of adenocarcinoma. Gastroenterology 1987; 93: 111.
  • 10
    Brand DL, Ylvisakar JF, Gelfand M, Pope CE. Regression of the columnar esophageal (Barrett's) epithelium after anti-reflux surgery. N Engl J Med 1980; 302: 8448.
  • 11
    Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR. Barrett's esophagus. Ann Surg 1983; 198: 55465.
  • 12
    Starnes BA, Adkins RB, Ballinger JF. Barrett's esophagus: a surgical entity. Arch Surg 1984; 119: 5637.
  • 13
    Williamson WA, Ellis FH, Gibb SP, Shahian DM, Aretz HT. Effects of anti-reflux operation on Barrett's mucosa. Ann Ther Surg 1990; 49: 53742.
  • 14
    Barham CP, Jones RL, Biddlestone IR, et al. Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation. Gut 1997; 41: 2814.
  • 15
    Basu KK, Pick B, Bale R, et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 2002; 51: 77680.
  • 16
    Sampliner RE, Faigel D, Fennerty MB, et al. Effectiveness and safe endoscopic reversal of non dysplastic Barrett's esophagus with thermal electrocoagulation combined with high dose acid inhibition. Gastrointest Endosc 2001; 53: 5548.
  • 17
    Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow up of 100 patients. Gastrointest Endosc 1999; 49: 17.
  • 18
    Deviere J. Barrett's oesophagus: the new endoscopic modalities have a future. Gut 2005; 54: i338.
  • 19
    Berensen MM, Johnson TD, Markowitz NR, Samowitz WS. Restoration of squamous epithelium after ablation of Barrett's esophagus. Gastroenterology 1993; 104: 168691.
  • 20
    Cooper BT, Barbezat GO. Treatment of Barrett's with H2 blockers. J Clin Gastroenterol 1987; 9: 13941.
  • 21
    Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995; 9: 4514.
  • 22
    Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole therapy. Gut 1999; 45: 48994.
  • 23
    Klinkenberg-Knoll EC, Festen HP, Jansen JB, et al. Long term treatment with omeprazole for erosive esophagitis. Ann Intern Med 1994; 121: 1617.
  • 24
    Sharma P, Sampliner RE, Camargo E. Normalisation of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 5825.
  • 25
    Weinstein WF, Lieberman DA, Landis KJ, Weber LJ, Berger ML, Ippoliti AF. Omeprazole induced regression of Barrett's esophagus: a two year randomized controlled double blind trial. Gastroenterology 1996; 110: A294.
  • 26
    Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12: 8937.
  • 27
    Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long term therapy with high dose omeprazole. Gastrointest Endosc 1996; 44: 7005.
  • 28
    Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar lined Barrett's oesophagus with omeprazole 40 mg daily: results of five years continuous therapy. Aliment Pharmacol Ther 1999; 13: 12059.
  • 29
    Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999; 94: 34206.
    Direct Link:
  • 30
    Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO. Maximal acid reflux control: feasible and effective. Aliment Pharmacol Ther 2001; 15: 51924.
  • 31
    Howden CW, Horning CA. Do proton pump inhibitors induce regression in Barrett's esophagus? Gastroenterology 1997; 112: A152.
  • 32
    Jankowski JA, Provenzale D, Moayyeddi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122: 58891.
  • 33
    Sampliner RE, Steinbronn K, Garewal HS, Riddell RH. Squamous mucosa overlying columnar epithelium in Barrett's esophagus in the absence of anti-reflux surgery. Am J Gastroenterol 1988; 83: 5102.
  • 34
    Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 2125.
  • 35
    Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 3338.
  • 36
    Jankowski JA, Anderson M. Review article: Management of oesophageal adenocarcinoma – control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Aliment Pharmacol Ther 2004; 20 (Suppl. 5): 7180.
  • 37
    Gladman L, Chapman W, Iqbal TH, Cooper BT. Barrett's oesophagus: an audit of surveillance over 15 years. Gut 2004; 53: A54.
  • 38
    Basu KK, de Caestecker JS. Audit of a Barrett's epithelium surveillance database. Eur J Gastroenterol Hepatol 2004; 16: 1715.
  • 39
    Murray L, Watson P, Johnston B, Sloan J, Mainie IML. Risk of adenocarcinoma in Barrett's oesophagus: a population based study. BMJ 2003; 327: 5345.
  • 40
    Solaymani-Dodaran M, Logan RFA, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53: 10704.
  • 41
    Hammeetman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 124956.
  • 42
    Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow cytometry and histological progression to malignancy in Barrett's esophagus. Gastroenterology 1992; 102: 12129.
  • 43
    Vieth M, Stolte M. Barrett's esophagus and neoplasia. Gastroenterology 2002; 122: 590.
  • 44
    Fitzgerald RC. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut 2005; 54: i216.
  • 45
    Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus: an ex vivo differentiation and proliferation model. J Clin Invest 1996; 68: 21208.
  • 46
    Souza RF, Shewmake K, Terada LS, et al. Acid exposure activates mitogen activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122: 299307.
  • 47
    Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclo-oxygenase 2 in Barrett's esophagus and associated adenocarcinoma. Cancer Res 1998; 58: 292934.
  • 48
    Shirvani V, Ouatu-Luscar R, Kaur B, et al. Cyclo-oxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 46796.
  • 49
    Ouatu-Luscar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 3275.
  • 50
    Umansky M, Yasui W, Hallak A, et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001; 20: 798791.
  • 51
    Kaur BS, Khamnehei N, Iravani M, et al. Rofecoxib inhibits cyclo-oxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 607.
  • 52
    Spechler S, Lee E, Ahnen D, et al. Long term outcome of medical and surgical treatments for gastro-esophageal disease: follow up of a randomised trial. J Am Med Assoc 2001; 285: 23318.
  • 53
    Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastro-esophageal diseases and after anti-reflux surgery. Gastroenterology 2001; 121: 128693.
  • 54
    Luostarinen M, Isolauri J, Laitinen J, et al. Fate of Nissen fundoplication after 20 years. A clinical, endoscopical and functional analysis. Gut 1993; 34: 101520.
  • 55
    Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180: 38791.
  • 56
    Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other non-steroidal anti-inflammatory drugs and the risk esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97102.
  • 57
    Basetti C, Talamini R, Franceschi SS, et al. Asprin use and cancers of the upper aerodigestive tract. Br J Cancer 2003; 88: 6724.
  • 58
    Castell DO. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 98991.
  • 59
    Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalisation of intra-esophageal acid reflux in patients Barrett's esophagus. Am J Gastroenterol 1998; 93: 7116.
    Direct Link: